SALT LAKE CITY, Sept. 3, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), a company focused on discovering, developing and commercializing novel, small molecule drugs for the treatment of cancer and HIV infection, today announced that Adrian N. Hobden, President and CEO of Myriad Pharmaceuticals, will provide an overview of the Company at the following conferences:
